Emergency Use Authorizations

OraQuick® Ebola Rapid Antigen Test (OraSure Technologies, Inc.) – For Use with whole Blood – July 31, 2015 On July 31, 2015, the FDA issued an Emergency Use Authorization (EUA) to authorize the emergency use of the OraQuick® Ebola Rapid Antigen Test for the presumptive detection of Ebola Zaire virus (detected in the West Africa…

Evaluation and Reporting of Age, Race, and Ethnicity Data in Medical Device Clinical Studies

%PDF-1.7 % 2061 0 obj stream x]ksu_ߍJZykyII*JQ”%*f(l~?s`rh1[~ǹn?z~~t~1%}wrt|rˣ7’O^-~~⿫Rc*_=~/M⠩SV;MlֶXj*ZTSVPd6Woq.I6:V֧:7|Tʣ9g-=5U5ҁp8mc4ġO:VMu|B3-[{NM+iyLVinz,quvB]Iڒ/2.DPW+hE M|CYۚ:ʠmV*’?dlnɼ C`ۄ)Iʢ[9ZrWce*r6NƐ”~89/ˣ”!XDJ Ķm-z2©D;ɦ@’+Z%wclJdXjb4mC7pup4)sNrJeb”vQ(Ef,ҥ ʉ;ȷPPeefPTUh-cAYRESK9YȺ:dEiUDх,+(ox2JO`5m-0N`^[̰VY

Announcing Final Guidance on Use of International Standard ISO 10993-1, "Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process" and FDA Webinar on the Final Guidance

On July 21, 2016, the FDA will hold a webinar for industry to review the Use of International Standard ISO 10993-1, “Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process” final guidance document. The recommendations in this final guidance clarify and update how medical device developers may use…

Webinar – Draft Guidance: 'Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions'

On Monday, July 11, 2016, the FDA will host a webinar to share information and answer questions about its draft guidance entitled ‘Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions.’ This draft guidance released on June 15, 2015, focuses on the factors the FDA may consider when making decisions…